<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204709">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000262</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-08391-14</org_study_id>
    <secondary_id>R01DA008391</secondary_id>
    <secondary_id>R01-08391-14</secondary_id>
    <nct_id>NCT00000262</nct_id>
  </id_info>
  <brief_title>Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14</brief_title>
  <official_title>Effects of Combined Sevoflurane and Nitrous Oxide Inhalation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of combined sevoflurane and nitrous
      oxide inhalation on mood, psychomotor performance, and the pain response in humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 1996</start_date>
  <completion_date type="Actual">February 1999</completion_date>
  <primary_completion_date type="Actual">February 1999</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain intensity, pain bothersomeness</measure>
    <time_frame>During inhalation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mood</measure>
    <time_frame>During inhalation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psychomotor performance</measure>
    <time_frame>During inhalation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Inhalation was for 68 min divided into 4 blocks with nitrous oxide added during either block 2 or block 4</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Placebo +/- 30% Nitrous oxide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane 0.2% +/- 30% Nitrous oxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane 0.4% +/- 30% Nitrous oxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30% Nitrous oxide</intervention_name>
    <arm_group_label>Placebo +/- 30% Nitrous oxide</arm_group_label>
    <arm_group_label>Sevoflurane 0.2% +/- 30% Nitrous oxide</arm_group_label>
    <arm_group_label>Sevoflurane 0.4% +/- 30% Nitrous oxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.4% Sevoflurane</intervention_name>
    <arm_group_label>Sevoflurane 0.4% +/- 30% Nitrous oxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.2% sevoflurane</intervention_name>
    <arm_group_label>Sevoflurane 0.2% +/- 30% Nitrous oxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo +/- 30% Nitrous oxide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Please contact site for information.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Zacny, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago, Anesthesia &amp; Critical Care</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 26, 2015</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nitrous oxide</keyword>
  <keyword>sevoflurane</keyword>
  <keyword>drug interaction</keyword>
  <keyword>subjective effects</keyword>
  <keyword>analgesia</keyword>
  <keyword>healthy volunteers</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nitrous Oxide</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
